“My first few weeks as Interim CEO of Akari have been filled with non-stop activity and optimism,” said Samir Patel, MD, Akari Interim President and CEO. “We continue to work towards completion of the merger with Peak Bio, advance PAS-nomacopan in geographic atrophy, and explore value creation through business opportunities with nomacopan, a phase 3 ready compound. In addition, we continue to be incredibly optimistic about the potential opportunities afforded by Peak’s ADC platform technology.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics Announces Major Restructuring and Cost Cuts
- Akari Therapeutics Announces Post-Merger Strategic Advancements
- Peak Bio, Akari Therapeutics announce portfolio prioritization plan
- Akari Therapeutics, Peak Bio announce portfolio prioritization plan
- Akari CEO Jacques, COO Bradford-Klug step down, appoints Patel as interim CEO